Belite Bio, Inc

First half, 2022 financial results conference call. After today's presentation, there'll be an opportunity to ask questions. If the participant calling in would like to ask a question, please press star one one on your telephone keypad. If a participant joining via webcasting would like to ask a question, please submit questions by clicking on ask a question at the top right of your screen. Please note, this event is being recorded. Yesterday, Be Light Bio issued a news release announcing the company's financial results for the first half of fiscal 2022, and it's available within the news section of the company's IR website at www.investors.belightbio.com. Additionally, the presentation has been uploaded to the event section of the company's IR website. If participants joining via webcasting find that the slide presentation is not synchronizing, please refresh the webpage and make sure to click on the play icon at the bottom left corner. Alternatively, please visit the events section of our IR website to view the presentation. I'd like to remind you that the statements we are about to make today may include statements relating to Be Like Bio's business plans and future prospects that are forward-looking to the ending of the Private Securities Litigation Reform Act of 1995. These statements cover many events and matters that are subject to various risks that could cause actual results to differ materially from those expressed or implied in any forward-looking statement we make. I encourage you to review the forward-looking statement section included in our Form 6-K, furnished on August 10th, for a detailed description of the risk factors affecting our business that could cause those differences. In addition, any forward-looking statement mentioned above represents our views only as of today, and we do not undertake any obligation to update any forward-looking statement except as required under applicable law. Representing Be Like Bio today are Dr. Tom Lin, CEO, Dr. Nathan Mata, CSO, and Mr. Haoyuan Cheng, CFO. I'd now like to turn the call over to Tom. Tom?

Thanks, Chris, and thanks, everyone, for joining this call. I'm Tom Lin, CEO of Be Like Bio. And I'd just like to give a quick background on myself. I'm trained in medicine and surgery, and I also did my PhD in neurology, where my research focus was on developing treatments for neurodegenerative disease. For most of my career, I've led several novel drug governments in multiple therapeutic areas. And prior to founding Be Like Bio and Limbao Science, I've led two startup companies to IPO. On this call with me today is our CSO, Dr. Nathan Mata, and our CFO, Hao-Yuan Zhuang. Nathan, would you like to introduce yourself?

Sure. Thanks, Tom. Hello, everyone. I'm Nathan Mata. I am the Chief Scientific Officer for Be Light Bio. My PhD is in neurobiology. I have a master's degree in biochemistry as well. I've been in the biotech space for about 18 years. The majority of that 15 plus has been in ophthalmic drug development. specifically looking at advancing therapies, developing therapies for neurodegenerative diseases such as AMD and Stargardt's disease. I'm credited with leading the development of the first RBP4 antagonist in advanced RIMD and the first visual cycle modulator in both advanced RIMD and Stargardt's disease. And I look forward to discussing more with you and showing you some of our data.